News and insights
LifeArc Ventures’ news, thought leadership, blogs, and our upcoming podcast series.
GlycoEra Appoints Andrea Matthews as Chief Business Officer to Support Next Phase of Company Growth
Posted September 22, 2026
Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer
Posted September 9, 2026
Etienne Cousin joins LifeArc Ventures
Posted July 27, 2026
Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802
Posted June 22, 2026
Posted June 12, 2026
AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026
Posted May 14, 2026
Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board
Posted May 14, 2026
AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid
Posted May 4, 2026
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round
Posted May 1, 2026
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial
Posted April 1, 2026
We’re growing our LifeArc Ventures team!
Posted February 12, 2026
LifeArc Ventures – A Year in Review
Posted January 29, 2026
Posted January 20, 2026
Posted January 20, 2026
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
Posted January 8, 2026
Fluid Biomed Appoints Veteran MedTech Executive John Kilcoyne as Independent Board Chair
Posted November 24, 2025
Managing Partner Clare Terlouw features in the latest edition of Leading Beyond the Lab
Posted November 20, 2025
Jonathan Nash congratulates Affect Therapeutics, on their successful $26 million Series B funding
Posted November 6, 2025
Affect Therapeutics Raises $26 Million Series B
Posted November 5, 2025
Posted November 3, 2025
Posted October 1, 2025
Olivia Cavlan joins LifeArc Ventures
Posted September 29, 2025
Posted September 24, 2025
Posted September 12, 2025
Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
Posted August 28, 2025
Rising Leaders – Aneesh Karatt-Vallatt talks to Jo Shorthouse on Maxion Therapeutics’ antibody revolution
Posted August 21, 2025
Posted June 18, 2025
Posted June 16, 2025
Posted June 13, 2025
Posted June 5, 2025
Preclinical data highlights potential of Ikarovec’s bicistronic gene therapy approach in common causes of vision loss
Posted May 29, 2025
Sohaib Mir, Partner at LifeArc Ventures congratulates new portfolio company, GlycoEra, on their $130m fundraise
Posted May 28, 2025
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
Posted May 28, 2025
Closed Loop Medicine appoints Kate Woolland as CEO
Posted May 21, 2025
Ikarovec appoints Thomas Ciulla MD MBA, expert in ophthalmology drug development, as President and CEO
Posted May 6, 2025
AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN
Posted May 2, 2025
Tribune Therapeutics Raises EUR 37 Million
Posted March 26, 2025
Tribune Therapeutics Raises EUR 37 Million for Next-Generation Anti-Fibrotic Therapies
Posted March 26, 2025
Posted March 25, 2025
Hillstar Bio closes $67 million Series A financing round
Posted March 25, 2025
Posted March 25, 2025
LifeArc invests in Maxion Therapeutics Series A
Posted March 17, 2025
Posted March 17, 2025
LifeArc Ventures 2024: new investments, targeted follow-ons and substantive portfolio progress
Posted January 30, 2025
Sword Health Acquires Surgery Hero to Accelerate Global Growth and Expand its Presence in the UK
Posted January 24, 2025
Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802
Posted January 17, 2025
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
Posted January 9, 2025
Clare Terlouw, Head of LifeArc Ventures, talks to In Vivo’s Ashley Yeo on the improving investment climate
Posted December 19, 2024
LifeArc invests in Fluid Biomed
Posted December 17, 2024
Ikarovec’s seed round extension brings total to £8M with proceeds to advance lead sight loss programme towards clinic
Posted October 23, 2024
Posted October 8, 2024
Cumulus Neuroscience Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024
Posted September 24, 2024
Tina Sampath has been promoted to Interim CEO
Posted September 24, 2024
Posted September 17, 2024
Surgery Hero wins prestigious NIHR grant to fund long-term study for patients undergoing hip and knee replacement surgery
Posted September 2, 2024
Cumulus Neuroscience Presents Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
Posted August 1, 2024
Cumulus Neuroscience to Present Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
Posted July 18, 2024
ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
Posted July 3, 2024
Posted April 15, 2024
Clare Terlouw Rising Leader Interview with In Vivo
Posted April 9, 2024
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines
Posted March 26, 2024
Posted March 15, 2024
Posted March 12, 2024
Closed Loop Medicine demonstrates application of novel drug plus software product for personalized treatment of hypertension
Posted February 8, 2024
Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO
Posted February 1, 2024
Posted January 25, 2024
Posted November 7, 2023
Posted October 25, 2023
Posted October 10, 2023
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
Posted September 22, 2023
Posted August 4, 2023
Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference
Posted July 18, 2023
LifeArc Ventures Invests in Affect Therapeutics $16 million Series A to Deliver Next Generation Addiction Recovery
Posted July 12, 2023
Cumulus Neuroscience to Present Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference
Posted July 11, 2023
Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning,First-In-Class NeurophysiologyPlatform for At-Home Use
Posted June 1, 2023
Cumulus Neuroscience LandsCoveted iF Design and Red DotAwards for Innovative At-Home EEGDevice
Posted June 1, 2023
Closed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeutics
Posted May 18, 2023
Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use
Posted May 10, 2023
Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat” autoimmune diseases
Posted April 19, 2023
Posted April 12, 2023
AbCellera and RQ Bio Partner
Posted March 27, 2023
International Women’s Day
Posted March 8, 2023
Posted February 23, 2023
Posted February 15, 2023
Posted February 10, 2023
Cumulus Neuroscience appoints SiggiSaevarsson as COO
Posted February 10, 2023
RQ Bio Strengthens Board with Industry-leading Infectious Disease Experts Joining as Non- Executive Directors
Posted February 9, 2023
Posted February 1, 2023
Posted February 1, 2023
Posted January 10, 2023
LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Posted November 15, 2022
AbbVie acquires LifeArc portfolio company DJS Antibodies
Posted October 20, 2022
Cumulus Neuroscience appoints digitalhealth and pharmaceutical executive AmanBhatti, MD as Chief Executive Officer
Posted September 21, 2022
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
Posted September 8, 2022
New study highlights superior efficacy of at-home dry EEG assessment compared to lab-based monitoring
Posted August 10, 2022
Cumulus Neuroscience commences clinicalstudies of digital biomarker platform indegenerative neurological diseases
Posted May 25, 2022
Posted December 2, 2021
Posted November 16, 2021
Posted November 4, 2021
LifeArc invests in company developing personalised drug and digital combination treatments
Posted November 3, 2021
Posted October 25, 2021
LifeArc invests in Cumulus Neuroscience
Posted May 4, 2021
LifeArc co-leads £6 million funding in DJS Antibodies
Posted December 22, 2020
Posted September 23, 2020
LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases
Posted August 29, 2019
LifeArc invests £1.5 million in Ducentis BioTherapeutics
Posted June 14, 2019